Association of XRCC2 rs2040639 with the survival of patients with oral squamous cell carcinoma undergoing concurrent chemoradiotherapy.

CONCLUSION: The A-allele of XRCC2 rs2040639 is a favorable prognostic factor for disease-free survival. Patients with these genotypes may benefit from concurrent chemoradiotherapy. Additional confirmation from studies with larger samples or other ethnic populations is warranted. PMID: 33144272 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33144272?dopt=Abstract

Source: Gene - October 31, 2020 Category: Genetics & Stem Cells Authors: Senghore T, Wang WC, Chien HT, Chen YX, Young CK, Huang SF, Yeh CC Tags: Gene Source Type: research